ROXADUSTAT

Information current as at: 1 June 2026

The pharmaceutical company has advised that it is not proceeding in the PBS listing process at this time. The process for listing this medicine has ceased.

PBAC meeting date: March 2021

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: Evrenzo®
Form and strength:: Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:: Astrazeneca Pty Ltd
Condition/indication: (therapeutic use): Anaemia associated with chronic kidney disease
Listing requested:: Please see PSD for more information
Funding program:: Please see PSD for more information
Request authority level:: Please see PSD for more information
PBAC Submission type:: New listing (Major Submission)
Comment:: --
Other PBAC consideration:: --

Progress Details

Submission received for:: March 2021 PBAC meeting
Opportunity for consumer comment:: Not applicable
PBAC meeting:: Not applicable
PBAC outcome published:: Not Applicable (see PBAC Outcomes)
Lodgement of required documentation:: Not applicable
Agreement to listing arrangements:: Not applicable
Government processes:: Not applicable
Medicine listed on the PBS:: Not applicable

Glossary

PBAC Outcome

PBAC Recommendation:

Please see the Outcomes from the relevant meeting for more information

Case ID

a315

Page last updated

31 March 2026

Return to the Medicine Status Listing

v.9.19